Return to CBI Antibody Core Home Page
  Return to biothreat/emerging pathogens list
    Return to typhus (Wilmington strain) ( Rickettsia typhi ) list


typhus (Wilmington strain) ( Rickettsia typhi )
slpT


Antibody Name/Abbreviation: slpT
CBI Antibody Core Code: A1456

"Lot" Number: 1 Position: 100 (1546-1645)
% Identical Homology of Target to Mouse Protein: 26% (NP_032197.2| glutamate receptor, ionotropic, NMDA2B (epsilon 2); GluRepsilon2)
Molecular Weight of fusion protein: 25 KDa

Target sequence used to make this antibody:
VGAKVTGSAMNINDIVIYPEIHSFVVHKVNGKLSKAQSML
DGQTAPFISQPDRTAKTSYNIGLSANIRSDAKMEYGIGYD
FNAASKYTAHQGTLKVRINF






Sequence Name: slpT
Full name: crystalline surface layer protein (slpT)
UniGene Number: N.A.
Accession Number: L04661
Source organism: typhus (Wilmington strain) ( Rickettsia typhi )
Full length size (aa): To be posted
NCBI information page: click here

Full length sequence:
MAQKPNFLKKIISAGLVTASTATIVAGFSGVAMGAVMQYNRTTNAAATTV
DGAGFDQTGAGVNLPVATNSVITANSNNAITFNTPNGNLNSLFLDTANTL
AVTINENTTLGFVTNVTKQGNFFNFTIGAGKSLTITGHGITAQQAATTKS
AQNVVSKVNAGAAINDNDLSGVGSIDFTAAPSVLEFNLINPTTQEAPLTL
GDNAKIVNGANGILNITNGFVKVSDKTFAGIKTINIGDNQGLMFNTTPDA
ANALNLQGGGNTINFNGRDGTGKLVLVSKNGNATEFNVTGSLGGNLKGVI
EFDTTAAAGKLIANGGAANAVIGTDNGAGRAAGFIVSVDNGNAATISGQV
YAKDIVIQSANAGGQVTFEHLVDVGLGGKTNFKTADSKVIITENASFGST
DFGNLAVQIVVPNNKILTGNFIGDAKNNGNTAGVITFNANGTLVSGNTDP
NIVVTNIKAIEVEGAGIVQLSGIHGAELRLGNAGSIFKLADGTVINGPVN
QNPLVNNNALAAGSIQLDGSAIITGDIGNGAVNAALQDITLANDASKILT
LSGANIIGANAGGAIHFQANGGTIQLTSTQNNILVDFDLDVTTDQTGVVD
ASSLTNNQTLTINGSIGTIGANTKTLGRFNVGSSKTILNAGDVAINELVM
ENDGSVHLTHNTYLITKTINAANQGKIIVAADPINTDTALADGTNLGSAE
SPLSNIHFATKAANGDSILHIGKGVNLYANNITTTDANVGSLHFRSGGTS
IVSGTVGGQQGLKLNNLILDNGTTVKFLGDITFNGGTKIEGKSILQISSN
YITDHIESADNTGTLEFVNTDPITVTLNKQGAYFGVLKQVMVSGPGNIAF
NEIGNGVAHAIAVDSISFENASLGASLFLLSGTPLDVLTIKSTVGNGTVD
NFNAPILVVSGIDSMINNGQVIGDQKNIIALSLGSDNSITVNSNTLYAGI
RTTKTNQGTVTLSGGIPNNPGTIYGLGLENGDPKLKQVTFTTDYNNLGSI
IATNVTINDDVTLTTGGIAGTDFDGKITLGSINGNANVKFVDRTFSHPTS
MIVSTKANQGTVTYLGNALVGNIGSSDIPVASVRFTGNDSGVGLQGNIHS
QNIDFGTYNLTILNSDVILGGGTTAINGEIDLLTNNLIFANGTSTWGNNT
SLSTTLNVSNGNVGQIVIAEGAQVNATTTGTTTIKIQDNANANFSGTQTY
TLIQGGARFNGTLGAPNFDVTGNNIFVKYELIRDANQDYVLTRTNDVLNV
VTTAVGNSAIANAPGVHQNIAICLESTDTAAYNNMLLAKDSSDVATFIGA
IATDTGAAVATVNLNDTQKTQDLLGNRLGALRYLSNSETADVGGSETGAV
SSGDEAIDQVSYGVWAKPFYNIAEQDKKGGLAGYKAKTAGVVVGLDTLAN
DNLMIGAAIGITKTDIKHQDYKKGDKTDIKGLSFSLYGAQQLVKNFFAQG
SAIFTLNKVKSKSQRYFFDANGKMNKQIAAGNYDNITFGGNLMFGYDYNA
LQGVLVTPMAGLSYLKSSNENYKETGTTVANKRIHSKFSDRIDLIVGAKV
TGSAMNINDIVIYPEIHSFVVHKVNGKLSKAQSMLDGQTAPFISQPDRTA
KTSYNIGLSANIRSDAKMEYGIGYDFNAASKYTAHQGTLKVRINF





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.